Seipel Group receives another Patent for Prorox® our prostate and bladder formula

Seipel Group has 3 patent families spanning 25 countries, and we have just been awarded a second patent on Prorox®, due to the uniqueness of the formulation, from the Australian Patent Office. The patent is for the Prevention or Treatment of Benign Prostatic Hyperplasia (BPH) and Related Disorders.

There has been a paradigm shift in the treatment of male LUTS (lower urinary tract symptoms) such as urinary frequency, urgency and getting up at night for the toilet. The convention has been to focus on the prostate, in particular BPH, but half the time male LUTS are caused by a bladder issue, commonly overactive bladder (OAB). Seipel Group’s Prorox® formula is a patented, effective herbal and nutritional formula that has been scientifically formulated to support both the prostate and the bladder.

We closely monitor the quality of all our ingredients to deliver products that can be trusted. Saw palmetto, for example, a key ingredient in our Prorox® formula is known to provide relief from benign prostatic hypertrophy (BPH), and it is widely used. It is an expensive ingredient and unfortunately there are numerous products on the market that use saw palmetto adulterated with animal fats and other substances. We source a wild-crafted product, and closely monitor the process of extracting the active ingredient from the berries, and screen for adulterations.

We aim to reach and maintain the highest standards in both product quality and efficacy. Our full accreditation status of Australian Trusted Trader (from The Department of Home Affairs and the Australian Border Force) testifies to the fact that our supply chain security and trade compliance meets the Australian Customs standards.